Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 39.68 -0.05% -0.02
EGRX closed down 0.05 percent on Wednesday, May 12, 2021, on 68 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical EGRX trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -0.05%
Earnings Movers Other -0.05%
Multiple of Ten Bearish Other -0.05%
Lower Bollinger Band Touch Weakness -0.05%
Oversold Stochastic Weakness -0.05%
180 Bearish Setup Bearish Swing Setup 3.15%
Expansion Breakdown Bearish Swing Setup 3.15%
Older End-of-Day Signals for EGRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 20 hours ago
Up 2% about 20 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Up 1% about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Eagle Pharmaceuticals, Inc. Description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Stroke Organic Chemistry Toxicology Chronic Lymphocytic Leukemia Lung Cancer Lymphocytic Leukemia Percutaneous Angioplasty Lung Cancers Small Cell Lung Cancers Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards

Is EGRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 55.43
52 Week Low 36.48
Average Volume 109,763
200-Day Moving Average 44.77
50-Day Moving Average 42.43
20-Day Moving Average 41.80
10-Day Moving Average 40.54
Average True Range 1.67
ADX 18.98
+DI 18.61
-DI 27.26
Chandelier Exit (Long, 3 ATRs ) 40.69
Chandelier Exit (Short, 3 ATRs ) 43.27
Upper Bollinger Band 45.16
Lower Bollinger Band 38.44
Percent B (%b) 0.18
BandWidth 16.10
MACD Line -0.83
MACD Signal Line -0.62
MACD Histogram -0.2085
Fundamentals Value
Market Cap 517.03 Million
Num Shares 13 Million
EPS 0.35
Price-to-Earnings (P/E) Ratio 113.70
Price-to-Sales 3.50
Price-to-Book 3.52
PEG Ratio 0.91
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.76
Resistance 3 (R3) 42.75 41.71 42.24
Resistance 2 (R2) 41.71 40.93 41.72 42.07
Resistance 1 (R1) 40.70 40.45 41.21 40.71 41.90
Pivot Point 39.66 39.66 39.92 39.67 39.66
Support 1 (S1) 38.65 38.88 39.16 38.66 37.46
Support 2 (S2) 37.61 38.40 37.62 37.29
Support 3 (S3) 36.60 37.61 37.12
Support 4 (S4) 36.61